NCT00976508

Figitumumab Combined With Pegvisomant For Advanced Solid Tumors

Phase 1 Safety And Tolerability Study Of Figitumumab Combined With Pegvisomant In Patients With Advanced Solid Tumors

• Status: Terminated
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 10 Years
• Healthy volunteers: Not accepted

Summary

This is a Phase 1 study investigating the safety and tolerability of Figitumumab plus Pegvisomant for treatment of advanced solid tumors.

Detailed description

This study was closed to enrollment on 18 April 2011 due to inability to recruit patients on a timely basis as well as business reasons. Study closure was not related to any safety concerns.

Conditions

• Colorectal Neoplasms
• Lung Neoplasms
• Breast Neoplasms
• Prostatic Neoplasms
• Sarcoma

Interventions

Type	Name	Description
DRUG	figitumumab	IGF-1R antibody, 20 mg/kg, IV every 3 weeks for up to 1 year
DRUG	pegvisomant	growth hormone antagonist, 10, 20 or 30 mg per day via subcutaneous injection for up to 1 year

Timeline

• Start date: 2009-11-01
• Primary completion: 2011-09-01
• Completion: 2012-10-01
• First posted: 2009-09-14
• Last updated: 2013-12-13
• Results posted: 2013-12-13

Locations

5 sites across 4 countries: United States, Canada, Finland, Germany